{"id":"NCT04531982","sponsor":"ACADIA Pharmaceuticals Inc.","briefTitle":"Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-08-05","primaryCompletion":"2024-01-25","completion":"2024-02-19","firstPosted":"2020-08-31","resultsPosted":"2025-04-01","lastUpdate":"2025-08-22"},"enrollment":454,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Pimavanserin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Drug - Pimavanserin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of negative symptoms of schizophrenia","primaryOutcome":{"measure":"Negative Symptom Assessment-16 (NSA-16) Total Score - Change From Baseline to Week 26","timeFrame":"26 Weeks Treatment Duration","effectByArm":[{"arm":"Drug - Pimavanserin","deltaMin":-12.14,"sd":10.29},{"arm":"Placebo","deltaMin":-11.09,"sd":9.18}],"pValues":[{"comp":"OG000 vs OG001","p":"0.4825"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":102,"countries":["Argentina","Bulgaria","Croatia","Czechia","Hungary","Italy","Lithuania","Poland","Russia","Serbia","Spain","Ukraine"]},"refs":{"pmids":["36190440"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":227},"commonTop":["Headache"]}}